China Resources Medical Holdings Company Limited (CR Medical, stock code: 1515) entered into a new Pharmaceuticals, Medical Devices and Medical Consumables (PMM) framework agreement with its controlling shareholder, China Resources (Holdings) Company Limited (CRH). The validity period extends from January 1, 2026, to December 31, 2028. Under the agreement, members of CRH may supply PMM Items to CR Medical under renewed annual caps set at RMB1,600 million, RMB1,650 million, and RMB1,700 million for the years 2026, 2027, and 2028, respectively. As CRH is a controlling shareholder and thus a connected person under Chapter 14A of the Listing Rules, these transactions require reporting, annual review, announcement, and approval by Independent Shareholders.

The proposed arrangement reflects expectations for continued growth in CR Medical’s hospital network, broader supply chain integration, and a provision for possible industry-wide cost changes. An Extraordinary General Meeting (EGM) will be convened for Independent Shareholders to consider and vote on the relevant resolutions. A circular containing details of the framework agreement, recommendations by the Independent Board Committee, a report from the Independent Financial Adviser, and other relevant information is scheduled for release on or before December 29, 2025. CRH and its associates, having a material interest in the agreement, will abstain from voting at the EGM.